相关实验视频

Updated: Jul 18, 2026

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

检测血cf-nDNA和cf-mtDNA的诊断值,以检测帕金森病和多个系统缩

Chao Ying^1,2,3,4, Yuan Li⁵, Hui Zhang⁵

¹Department of Neurobiology, Xuanwu Hospital, Capital Medical University, Beijing, China.

Frontiers in neuroscience

|December 17, 2024

概括

无等离子细胞核DNA (cf-nDNA) 和线粒体DNA (cf-mtDNA) 水平在帕金森病 (PD) 和多个系统缩 (MSA) 患者之间没有差异. 然而,cf-nDNA水平与PD和MSA患者的临床症状相关.

科学领域:

神经科学是一个神经科学.
遗传学遗传学是一种遗传学.
生物化学生物化学

背景情况:

异常性帕金森病 (PD) 和多个系统缩 (MSA) 的特征是细胞损失和线粒体功能障碍.
在PD和MSA的发病过程中,循环无细胞核DNA (cf-nDNA) 和线粒体DNA (cf-mtDNA) 的作用尚未完全被理解.

研究的目的:

研究患有PD和MSA的患者血cf-nDNA水平,cf-mtDNA复制数和cf-mtDNA完整性的变化.
确定这些无细胞DNA (cfDNA) 生物标志物是否可以预测PD或MSA的发展.

主要方法:

使用定量PCR测量了171名参与者的血cf-nDNA水平,cf-mtDNA拷贝数和cf-mtDNA缺失水平 (76名对照组,62名PD患者,33名MSA患者).
一般化的线性模型和逻辑回归被用于分别分析生物标志物差异和预测值.
斯皮尔曼相关性评估了cfDNA生物标志物,人口统计和临床尺度之间的关联.

主要成果:

在PD,MSA和对照组之间没有发现血cf-nDNA,cf-mtDNA拷贝数或cf-mtDNA删除水平的显著差异.
这些cfDNA测量没有预测患PD或MSA的风险.
在cf-nDNA水平和临床症状之间观察到相关性,包括PD患者的焦虑和MSA患者的动力衰竭和认知功能. 患有便秘的PD患者表现出较低的cf-mtDNA复制数,而患有认知障碍的MSA患者的cf-nDNA水平较高.

结论:

血cf-nDNA和cf-mtDNA生物标志物对PD和MSA的诊断实用性有限.
观察到cfDNA生物标志物与临床症状之间的相关性表明,细胞损失和线粒体功能障碍在PD和MSA发展中起着作用.

关键词:

帕金森病是帕金森氏症的一种疾病.生物标志物生物标志物没有细胞的线粒体DNA DNA.没有细胞的核DNA.在循环中循环的无细胞DNA.诊断诊断诊断诊断诊断诊断多个系统缩.

更多相关视频

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

相关概念视频

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...